Arthroscopic Debridement Combined With Platelet-Rich Plasma is a Viable Option for the Treatment of Advanced Ankle Osteoarthritis.

IF 2.7 4区医学 Q1 ORTHOPEDICS

CARTILAGE Pub Date : 2025-09-19 DOI:10.1177/19476035251378223

Taihei Miura, Yasuyuki Jujo, Jun Horng Tan, Chu Kai Man, Masato Takao

{"title":"Arthroscopic Debridement Combined With Platelet-Rich Plasma is a Viable Option for the Treatment of Advanced Ankle Osteoarthritis.","authors":"Taihei Miura, Yasuyuki Jujo, Jun Horng Tan, Chu Kai Man, Masato Takao","doi":"10.1177/19476035251378223","DOIUrl":null,"url":null,"abstract":"ObjectiveTo assess the efficacy of arthroscopic debridement combined with platelet-rich plasma (PRP) therapy in treating advanced ankle osteoarthritis (OA).DesignThe data of 34 advanced ankle OA patients were retrospectively analyzed, with 17 patients undergoing arthroscopic debridement alone (No-PRP group) and 17 receiving debridement with PRP therapy (PRP group). The Self-Administered Foot Evaluation Questionnaire (SAFE-Q) was evaluated preoperatively and at 3, 6, and 12 months postoperatively. The complications were assessed throughout the follow-up period.ResultsIn the PRP group, all SAFE-Q subscales significantly improved at 6- and 12-month post-treatment compared with baseline (P < 0.05), whereas improvements in the No-PRP group were limited. For severe ankle OA patients, only the pain-related subscale of the SAFE-Q significantly improved from baseline in the No-PRP group (P < 0.05). In contrast, all SAFE-Q subscales demonstrated significant improvement at 12 months postoperatively in the PRP group (P < 0.05). The recurrence rates were 23.5% in the No-PRP group and 11.8% in the PRP group.ConclusionArthroscopic debridement combined with PRP therapy for advanced ankle OA significantly improved all SAFE-Q subscales postoperatively, whereas debridement alone had limited benefits. This combination may offer an effective treatment for advanced ankle OA.","PeriodicalId":9626,"journal":{"name":"CARTILAGE","volume":" ","pages":"19476035251378223"},"PeriodicalIF":2.7000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449301/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CARTILAGE","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/19476035251378223","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

ObjectiveTo assess the efficacy of arthroscopic debridement combined with platelet-rich plasma (PRP) therapy in treating advanced ankle osteoarthritis (OA).DesignThe data of 34 advanced ankle OA patients were retrospectively analyzed, with 17 patients undergoing arthroscopic debridement alone (No-PRP group) and 17 receiving debridement with PRP therapy (PRP group). The Self-Administered Foot Evaluation Questionnaire (SAFE-Q) was evaluated preoperatively and at 3, 6, and 12 months postoperatively. The complications were assessed throughout the follow-up period.ResultsIn the PRP group, all SAFE-Q subscales significantly improved at 6- and 12-month post-treatment compared with baseline (P < 0.05), whereas improvements in the No-PRP group were limited. For severe ankle OA patients, only the pain-related subscale of the SAFE-Q significantly improved from baseline in the No-PRP group (P < 0.05). In contrast, all SAFE-Q subscales demonstrated significant improvement at 12 months postoperatively in the PRP group (P < 0.05). The recurrence rates were 23.5% in the No-PRP group and 11.8% in the PRP group.ConclusionArthroscopic debridement combined with PRP therapy for advanced ankle OA significantly improved all SAFE-Q subscales postoperatively, whereas debridement alone had limited benefits. This combination may offer an effective treatment for advanced ankle OA.

查看原文本刊更多论文

关节镜清创联合富血小板血浆是治疗晚期踝关节骨关节炎的可行选择。

目的评价关节镜下清创联合富血小板血浆（PRP）治疗晚期踝关节骨关节炎（OA）的疗效。回顾性分析34例晚期踝关节骨性关节炎患者的资料，其中单纯关节镜清创17例（No-PRP组），PRP联合清创17例（PRP组）。术前、术后3个月、6个月和12个月对自我管理足部评估问卷（SAFE-Q）进行评估。随访期间对并发症进行评估。结果与基线相比，PRP组在治疗后6个月和12个月的所有SAFE-Q量表均有显著改善（P < 0.05），而No-PRP组的改善有限。对于严重踝关节OA患者，无prp组只有SAFE-Q的疼痛相关亚量表较基线有显著改善（P < 0.05）。相比之下，PRP组所有SAFE-Q量表在术后12个月均有显著改善（P < 0.05）。无PRP组复发率为23.5%，PRP组为11.8%。结论关节镜清创联合PRP治疗晚期踝关节骨性关节炎可显著改善术后所有SAFE-Q亚量表，而单纯清创的益处有限。这种组合可以有效治疗晚期踝关节骨关节炎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CARTILAGE ORTHOPEDICS-

CiteScore

6.90

自引率

7.10%

发文量

期刊介绍： CARTILAGE publishes articles related to the musculoskeletal system with particular attention to cartilage repair, development, function, degeneration, transplantation, and rehabilitation. The journal is a forum for the exchange of ideas for the many types of researchers and clinicians involved in cartilage biology and repair. A primary objective of CARTILAGE is to foster the cross-fertilization of the findings between clinical and basic sciences throughout the various disciplines involved in cartilage repair. The journal publishes full length original manuscripts on all types of cartilage including articular, nasal, auricular, tracheal/bronchial, and intervertebral disc fibrocartilage. Manuscripts on clinical and laboratory research are welcome. Review articles, editorials, and letters are also encouraged. The ICRS envisages CARTILAGE as a forum for the exchange of knowledge among clinicians, scientists, patients, and researchers. The International Cartilage Repair Society (ICRS) is dedicated to promotion, encouragement, and distribution of fundamental and applied research of cartilage in order to permit a better knowledge of function and dysfunction of articular cartilage and its repair.